UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of report (Date of earliest event reported):  December 9, 2013

 

BIO-PATH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Utah 000-53404 87-0652870

(State or other jurisdiction

of incorporation)

 (Commission File Number) (IRS Employer Identification No.)

 

  

2626 South Loop, Suite 180, Houston, Texas 77054
(Address of principal executive offices) (Zip Code)

 

(832) 971-6616

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01 Other Events.

 

On December 9, 2013, Bio-Path Holdings, Inc. issued a press release titled “Preliminary Results from Bio-Path Holdings’ Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.”

 

A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

Description
  
99.1Press Release dated December 9, 2013

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIO-PATH HOLDINGS, Inc.
       
Dated:  December 9, 2013 By:   /s/ Peter H. Nielsen  
    Peter H. Nielsen
    President and Chief Executive Officer

 
 

  

EXHIBIT INDEX

 

Exhibit

Number

Description
  
99.1Press Release dated December 9, 2013